Litcius/Paper detail

Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib)

Sana M. Al‐Khatib, Sean D. Pokorney, Hussein R. Al‐Khalidi, Kevin Haynes, Crystal Garcia, David Martin, Jennifer C. Goldsack, Thomas Harkins, Noelle M. Cocoros, Nancy D. Lin, Hana Lipowicz, Debbe McCall, Vinit Nair, Lauren E. Parlett, Cheryl N. McMahill‐Walraven, Richard Platt, Christopher B. Granger

2020American Heart Journal23 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAtrial fibrillationRandomized controlled trialWarfarinRivaroxabanPopulationOral anticoagulantIntensive care medicineInternal medicineCardiologyEnvironmental healthAtrial Fibrillation Management and OutcomesVitamin K Research StudiesVenous Thromboembolism Diagnosis and Management
Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib) | Litcius